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ABSTRACT 
Objective: A rapid and reproducible HPLC method has been developed for the determination of enalapril in experimental combined dosage forms 
containing bisoprolol and enalapril and for drug dissolution studies.  
Methods: The separation was done using a column Hi Qsil C18
Results: The method was validated as per ICH guidelines. Under these conditions, enalapril was eluted at 5.33 min. Total run time was shorter than 
6 min. A linear relationship between the concentration and the area of chromatographic peaks of enalapril in the range of 1.250 mg/ml–10.000 
mg/ml (7.500 mg/ml at pH 1.2) was established. Requirements for linear dependency parameters are performed in this case throughout the range 
of application of the technique. Linearity studies were conducted in a wide range of concentrations (25-200% at pH 4.5 and 6.8, 25-150% at pH 1.2). 
In the medium with pH 1.2 release of enalapril from tablets in 5 min is 83.38 %, after 15 min-94.11%, after 30 min-97.17 %; in medium with pH 4.5 
the release of enalapril from tablets in 5 min makes 47.13 %, after 15 min-88.34 %, after 30 min-95.86 %; in a medium with pH 6.8, the release of 
enalapril from tablets in 5 min is 71.04 %, and after 15 min-88.88 %, after 30 min-92.11 %.  
 (4.6х250 mm, 5 μm particle size) and a mobile phase of methanol: phosphate buffer 
solution (65:35, v/v), flow-rate of 1.0 ml/min. The injection volume was 300 μL and the ultraviolet detector was set at 225 nm.  
Conclusion: A simple and sensitive HPLC method was developed for the estimation of enalapril in tablets containing enalapril and bisoprolol. The 
proposed method was applied successfully for quality control assay of enalapril in experimental tablets and in vitro dissolution studies.  
Keywords: Enapalril, High-performance liquid chromatography, Dissolution study, Validation 




The dissolution test for solid dosage is one of the main pharmaco-
technological tests used in the development, as well as during the 
life cycle of medicines. The main attention is paid to the study of the 
dissolution kinetics of the API, which is key in the selection and 
evaluation of the composition of the drug in the development 
process. The kinetics of dissolution or dissolution profiles is the 
dependence of the API concentration on the release time.  
The study of dissolution profiles is also used to prove the in vitro 
equivalence of generic drugs (according to the bioweaver 
procedure), as well as the introduction of registration changes 
(introduction of an alternative substance or auxiliary substance 
manufacturer, changes in the technology and composition of the 
drug, introduction of new dosage, etc.) [1]. 
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor 
widely used in the therapy of hypertension and heart 
failure. Enalapril is associated with a low rate of transient serum 
aminotransferase elevations and has been linked to rare instances of 
acute liver injury [2]. Chemical name of enapalril is (2S)-1-[(2S)-2-
[[(1S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl] 
pyrrolidine-2-carboxylic acid (fig. 1). 
 
 
Fig. 1: The chemical structures of enalapril maleate 
 
The State Pharmacopoeia of Ukraine (SPhU) has the monograph on 
the substance of enalapril maleate and on enalapril tablets. For 
identification of the substance of enalapril maleate, the SPhU offers 
the method of absorption spectrophotometry in the infrared region, 
quantitative determination–alkalimetry potentiometric titration. For 
identification of enalapril in tablets, the SPhU proposes TLC (mobile 
phase–a mixture of acetic acid of ice P, water P, butanol P (15:25:60). 
For the quantitative determination of enalapril in tablets–HPLC/UV 
(mobile phase–a mixture of acetonitrile P and solvent (40:60), 
solvent–potassium dihydrogen phosphate solution P, mobile phase 
rate–1.0 ml/min, detecting by the wavelength at 215 nm). 
There is an HPLC method described for the determination of 
enalapril in pharmaceutical preparations [2-5]. However, those 
methods are not developed for the determination of enalapril in 
dissolution studies while the dissolution profile of bisoprolol and 
another API from the combination drug product has not hitherto 
been reported in the literature [6-27]. In order to elucidate the 
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dissolution profiles bisoprolol and enalapril, a validated HPLC 
method is required for determination of enalapril from tablets in 
dissolution matrix.  
Therefore, the aim of this study was to develop and validate an 
efficient HPLC method for determination of enalapril and to 
introduce the dissolution profiles of tablets which contain bisoprolol 
and enalapril. Moreover, this new method could also be used for the 
routine analysis of enalapril in dosage forms, provided it is 
completely validated and rapid.  
The method was validated according to guidelines and applied for 
the assay of enalapril from their combination tablet dosage form. 
Also, in vitro dissolution of enalapril containing tablets were 
performed to validate the suitability of the proposed method. 
MATERIALS AND METHODS 
Instrumentation and chromatographic conditions  
The HPLC system consisted of Agilent 1260. A C18 column (Hi Qsil 
C18, 5 μm, 4.6х250 mm) was used for separation and quantification. 
The mobile phase consisted of methanol: phosphate buffer solution 
(65:35, v/v) and was filtered through a 0.45 μm filter and degassed 
before use. The injection volume was 300 μl and the ultraviolet 
detector was set at 225 nm. Analyses were run at a flow rate of 1.0 
ml/min at an ambient temperature (25 °C). The peak area was 
integrated automatically by using Empower® software. Under these 
conditions, enalapril was eluted at 5.33 min. Total run time was 
shorter than 6 min.  
Chemicals and reagents 
Standard enalapril was supplied by Refik Saydam National Public 
Health Agency. Methanol and phosphate buffer solution were of 
HPLC grade from Merck (Darmstadt, Germany) and all other 
reagents were analytical grade. Water obtained from the Milli-Q 
water system (Barnstead, USA) was used for the preparation of 
buffer and other aqueous solutions. Experimental tablets containing 
5 mg of enalapril and 2.5 mg of bisoprolol were developed by Prof. 
Kachrimanis Kyriakos (Department of Pharmaceutical Technology, 
Aristotle University of Thessaloniki, School of Pharmacy, 
Thessaloniki, Greece). 
Preparation of strock solution 
Standard stock solutions of enalapril were prepared separately by 
dissolving 50 μg of enalapril maleate in 50 ml appropriate solvent. 
These solutions were prepared freshly every week, during method 
development and application period.  
Preparation of calibration standards 
Calibration standards for enalapril (as maleate salt) (1.25, 2.0, 3.0, 
4.0, 10.0, 20.0, 30.0, 40 and 50.0 μg ml-1) were daily prepared from 
standard stock solutions by appropriate dilution processes using 
mobile phase.  
In vitro dissolution studies  
In vitro dissolution of twelve tablets containing bisoprolol and 
enalapril was performed using buffer solutions (pH 1.2; 4.5; 6.8) as 
the dissolution media at 50 rpm using an USP Apparatus II. The 
dissolution study was carried out in a 900 ml volume of buffer 
solution at 37 °C (±0.5) using the paddle method. One ml of sample 
was withdrawn and replaced with fresh dissolution medium at the 
time intervals of 5, 15, 30, 45 min. The concentrations of enalapril in 
samples were determined by the proposed HPLC method [28]. 
Analytical method validation 
Once the chromatographic and the experimental conditions were 
established, the method was validated by the determination of the 
following parameters such linearity range, sensitivity, repeatability, 
precision, accuracy, and specificity, as per ICH Q2 (R1) guidelines [29]. 
System suitability parameters 
The chromatographic systems used for analysis must pass system 
suitability before going to start the experiment. At first HPLC system 
is stabilized for forty minutes. Inject blank preparation (single 
injection) and standard preparation (six replicates) and record the 
chromatograms to evaluate the system suitability parameters such 
as tailing factor (NMT 1.5), theoretical plate count (NLT 3000) and 
retention time. The % RSD for the peak area of six replicate 
injections of bisoprolol fumarate standard NMT 2.0. The parameters 
such as tailing factor, % RSD and theoretical plates were studied. 
Linearity 
A standard stock solution of the enalapril maleate was prepared 
with the same solvent. To study the linearity range of drugs, 
serial dilutions were made from standard stock solution in the 
range of 25-200% of the nominal concentrations of enalapril in 
the test solution. 
Specificity  
Specificity of an analytical method is its ability to measure accurately 
and specifically the analyte of interest without interference from 
placebo and degradation products. The specificity of the method was 
established by injecting blank, placebo and standard solution in 
triplicate and recording the chromatograms. Blank solution 
shows no interference with any HPLC system artifact peak. Placebo 
to demonstrates the lack of interference
Chromatographic condition was optimized in several trials with the 
variation of the composition of mobile phase and flow rate. Based on 
the theoretical plates, peak shape and back pressure, the column 
was selected. The optimized mobile phase composition produced 
stable and acceptable peak shapes for enalapril and bisoprolol with 
mixtures of methanol: phosphate buffer solution (65:35, v/v) 
pumped at 1.0 ml/min flow rate and 225 nm UV detection 
wavelength. Therefore, all the experiments were carried out on a 
C18 column (Hi Qsil C18, 5 μm, 4.6х250 mm ). Under the optimum 
conditions, enalapril was eluted at 5.33 min.  
Representative chromatogram of enalapril maleate in tablets 
containing bisoprolol and enalapril is presented in fig. 2. 
The resultant chromatograms of blank, standard and sample were 
compared, the correlation was good between standard and sample 
and no interference of excipients in blank with drug was observed. 
Blank solution shows 
 from excipients. 
Precision 
The precision of the method was determined by repeatability 
(intraday) and intermediate precision (interday). Repeatability was 
determined by performing repeated analysis of the same working 
solution of enalapril maleate on the same day, under the same 
experimental conditions. The intermediate precision of the method 
was assessed by carrying out the analysis on different days and also 
by another analyst performing the analysis in the same laboratory 
(between-analysts). 
Accuracy 
The accuracy of a method is defined as the closeness of a measured 
value to the true value. The recovery studies were carried out at 25-
200 % of the target level in the tablet in triplicate each in the 
presence of placebo. 
RESULTS 
Optimization of chromatographic conditions 
no interference with any HPLC system artifact 
peak. Placeboto demonstrates the lack of interference
The proposed method was validated as to linearity range, sensitivity, 
repeatability, precision, accuracy, and specificity according to the 
ICH guidelines. 
 from 
excipients. The representative chromatogram (fig. 2) shows no other 
peaks in the retention time of bisoprolol and enalapril and retention 
times did not change. In addition, when the solution prepared from 
the blank tablet was injected into the HPLC system, no co-eluting 
peaks were obtained at the retention time of bisoprolol and 
enalapril.  
Method validation  
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Fig. 2: Representative chromatogram of enalapril maleate in combinated tablets 
 
System suitability  
A suitability test was applied to the chromatograms taken under 
optimum conditions to check various parameters such as column 
efficiency (plates), peak tailing, retention factor, and resolution. 
Suitable resolution (>2) and column efficiency (>1500 for both 
compounds) were achieved for the analysis method. The peak 
symmetries for both compounds were<1.2, whereas the capacity 
factors were>1.5. The analysis time was shorter than 6 min.  
Specificity 
Specificity was carried out by evaluation of blank, standard and 
sample were compared, the correlation was good between standard 
and sample and no interference of excipients in the blank with the 
drug was observed. Commonly used tablet excipients did not 
interfere with this method. It shows that the method is specific. The 
specificity results are tabulated in table 1. 
 
Table 1: Specificity study 
Name of the solution Retention time (tR) min 
mobile phase No peaks 
placebo No peaks 
bisoprolol fumarate (another API) 4.75 
Enalapril maleate 5.33 
 
Linearity range  
Calibration curve rеpresenting the rеlation betwеen the 
concеntrations of drugs versus the peak area was constructеd. In 
triplicatе run from which the linear regression equation was 
calculated. The results obtained were procеssed by the least squares 
method. The correlation coefficient of enalapril maleate was noted 
more than 0.9992 which states that the method was good linear to 
the concentration versus peak area responses. Results indicate high 
sensitivity of the proposed HPLC method. The calibration graph of 
enalapril maleate is presented in fig. 3, 4. 5 and characteristics of the 
linear dependence of enalapril maleate are listed in table 2. 
  
 
Fig. 3: Linearity on profils of dissolution test at pH 1.2 
 
Logoyda  




Fig. 4: Linearity on profils of dissolution test at pH 4.5 
 
 
Fig. 5: Linearity on profils of dissolution test at pH 6.8 
 
Table 2: Characteristics of the linear dependence of enalapril maleate 
рН Concentration range (mg/ml) Regression equation R Compliance with eligibility criteria 2 
1.2 1.250–7.500 y=26.3234 x-2.7878 0.9996 Corresponds 
4.5 1.250–10.000 y = 28.9882 x-19.4455 0.9992 Corresponds 
6.8 1.250–10.000 y = 26.7667x-12.7585 0.9993 Corresponds 
A linear relationship between the concentration and the area of chromatographic peaks of enalapril in the range of 1.250 mg/ml–10.000 mg/ml 
(7.500 mg/ml at pH 1.2) was established (table 1). Requirements for linear dependency parameters are performed in this case throughout the range 
of application of the technique. Linearity studies were conducted in a wide range of concentrations (25-200% at pH 4.5 and 6.8, 25-150% at pH 1.2). 
 
Accuracy and precision 
System precision is shown in table 3. Intra-day and inter-day % 
RSD values lower than 2% clearly assuring that this method was 
found to be fairly precise and reproducible (table 4). Regarding 
accuracy, a known amount of the standard drug was added to the 
fixed amount of pre-analyzed sample solution. % recovery was 
calculated by comparing the area before and after the addition of 
the standard drug. The standard addition method was performed 
at 25-200 % levels of concentrations. The high value of recoveries 
obtained for bisoprolol indicates that the proposed method was 
found to be accurate. 
  
Table 3: Results of system precision (n=5) 
Sample Peak area Injection no. RSD,, % 
Enalapril maleate 1086,486 1  




n is number of determinations, RSD is relative standard deviation 
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Table 4: Intra-day and Inter-day precision data of enalapril maleate (n=5) 
Day Intra-day precision Inter-day precision 
Mean RSD % Mean RSD % 
1 100.02 0.389 101.58 0.298 
2 100.87 0.291 99.99 0.267 
3 100.92 0.329 100.15 0.317 
n is number of determinations, RSD is relative standard deviation 
 
In vitro dissolution studies  
The average percentage of drugs released as detected by the 
proposed HPLC method after in vitro dissolution of tablets 
containing combination drug product are depicted in fig. 6-8.  
 
 








Fig. 8: In vitro dissolution profiles of enalapril at pH 6.8 
mean±SD, n=3 
As can be seen from fig. 6-8, in the medium with pH 1.2 release of 
enalapril from tablets in 5 min is 83.38 %, after 15 min-94.11%, 
after 30 min-97.17 %; in medium with pH 4.5 the release of enalapril 
from tablets in 5 min makes 47.13 %, after 15 min-88.34 %, after 30 
min-95.86 %; in a medium with pH 6.8, the release of enalapril from 
tablets in 5 min is 71.04 %, and after 15 min-88.88 %, after 30 min-
92.11 %.  
DISCUSSION 
The present RP-HPLC method is a simple, precise, specific, accurate 
and linear method for analyzing of enalapril in combinated tablets 
containing enalapril and bisoprolol. The previous study had 
reported that UV spectrophotometry methods and HPLC methods 
for enalapril and bisoprolol individually and in combination with 
other drugs but not together. In the present RP-HPLC method, we 
used UV detector which proves selectivity of the method for both 
APIs. The method was developed by using different buffer ratios at 
different flow rates. Finally methanol: phosphate buffer solution 
(65:35, v/v) as mobile phase and Hi Qsil C18
The method was validated as per ICH guidelines. Literature survey 
revealed, stability indicating RP-HPLC method for simultaneous 
estimation of enalapril with UV detector at different mobile phase 
and different column. Scientists Manindra M., Zafar H. S. and Ankur 
K. [30] described HPLC/UV method for the determination of 
enalapril maleate in tablets using the chromatography column 
Hypersil MOS, 5μ (250 mm x 4.6 mm) and mobile phase–a mixture of 
buffer solution and acetonitrile (40:60, v/v), flow rate–1.5 ml/min, 
wavelength detection–215 nm. Enalapril holding time was 9.72 min, 
longer than the present method. Compared to the previous method, 
this method is selective, simple, sensitive, and separation was done 
at shorter run time. The method was linear in the range of 
concentrations of 150-250 μg/ml, correlation coefficient was 0.9992.  
 (4.6х250 mm, 5 μm 
particle size) column as stationary phase was selected and 
separation was done for enalaprilat 5.33 min. 
The first step is to screen formulations with aqueous-based media in 
the range of pH 1.2, 4.5, 6.8 at the USP recommended ionic 
strength. For APIs that exhibit low solubilities in aqueous media 
throughout the pH range, the addition of surfactants is 
recommended. A medium resulting in a gradual increase of released 
drug up to 100% is preferred because it is more likely to detect 
differences in formulation or processing parameters [28]. 
The method was validated according to ICH guidelines and results 
were in compliance of ICH guidelines. The linearity of the method 
had a good correlation with concentration and peak area. The 
correlation coefficient of enalapril was found to be not less than 
0.9992, which indicates good linear relationship over concentration 
range 1.250-7.500/10.000 μg/ml. The % RSD values in intra-day and 
inter-day precision study were found to be less than 0.267 for 
enalapril, which indicate the method was precise. Hence, the present 
developed method was said to be suitable for the analysis of drugs in 
their pharmaceutical dosage form. Also, in vitro dissolution of 
enalapril containing tablets were performed to validate the 
suitability of the proposed method. The dissolution pattern complies 
with the FDA standards, indicating the suitability of the proposed 
method for the dissolution study of enalapril. It will allow 
conducting comparative studies in vitro to confirm the equivalence 
of tablets containing enalapril. 
CONCLUSION  
A rapid and reproducible RP-HPLC method has been developed for 
the determination of enalapril in experimental combined dosage 
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forms containing bisoprolol and enalapril. The present study of 
method development and method validation was per ICH guidelines, 
and it meets the acceptance criteria. The developed method can also 
be conveniently adopted for dissolution testing of tablets containing 
enalapril. The proposed method can help research studies, quality 
control and routine analysis with lesser resources available. 
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